Can entrectinib treat solid tumors?

Entrectinib can be used to treat some solid tumors. Entrectinib is a targeted therapy drug that mainly acts on tumors carrying ALK (tyrosine kinase) or ROS1 (ROS1 tyrosine kinase) gene fusion mutations. These gene mutations are found in a variety of solid tumors, including non-small cell lung cancer (NSCLC), breast cancer, gastrointestinal cancer, pancreatic cancer, neuroendocrine tumors, etc.

For patients with solid tumors carrying ALK or ROS1 fusion mutations, entrectinib has been confirmed to show significant therapeutic effects in some clinical trials. Clinical trial results show that entrectinib has achieved good results in controlling disease progression, alleviating symptoms, improving patients' quality of life, and prolonging survival.

Treatment of solid tumors is often a complex process involving the combined application of multiple treatments. In addition to targeted therapy drugs such as entrectinib, patients may also need to undergo other treatments such as surgery, radiotherapy, chemotherapy, and immunotherapy to achieve the best therapeutic effect.

However, it is important to note that not all patients with solid tumors are suitable for entrectinib treatment. The choice of treatment usually requires an individualized decision based on the patient's condition, medical history, type of genetic mutation, and other factors. Therefore, before starting entrectinib treatment, patients usually need to undergo genetic testing to confirm whether they carry ALK or ROS1 fusion mutations, and undergo physician evaluation and guidance to determine the most appropriate treatment plan.

In general, entrectinib, as a targeted therapy, has shown good efficacy in some patients with solid tumors carrying specific gene mutations. However, the best treatment plan for each patient should be considered and customized based on their individual circumstances. Therefore, patients should have a detailed discussion and evaluation with their doctor before undergoing treatment to ensure that the most appropriate treatment is selected.